In other malignancies, RUNX2 has been shown to drive expression of genes and pathways involved in invasion, angiogenesis, and metastasis such as MMP9, VEGF, IL-8, TGFβ, and AKT/PI3K (33), all of which have been reported as overexpressed by malignant T-cells from MF patients (34). The gene discussed is MMP9; the disease is mycosis fungoides.